GSK/Innoviva’s Trelegy Ellipta wins expanded nod for COPD
US regulators have approved GlaxoSmithKline and Innoviva’s Trelegy Ellipta to treat a wider population of chronic obstructive pulmonary disease (COPD) patients.
Read More
Tag: FF/UMEC/VI
GSK, Innoviva seek to expand scope of Trelegy Ellipta
GlaxoSmithKline and Innoviva have submitted new data to regulators in the US in support of expanding the label of Trelegy Ellipta in chronic obstructive pulmonary disease.
Read More
GSK, Innoviva’s Trelegy Ellipta cleared for COPD
GlaxoSmithKline and Innoviva have won European approval for the novel triple therapy inhaler Trelegy Ellipta, offering a new treatment option for patients with Chronic Obstructive Pulmonary Disorder (COPD).
Read More
GSK, Innoviva announce US nod for Trelegy Ellipta
GlaxoSmithKline and Innoviva have bagged a green light in the US for the novel triple therapy inhaler Trelegy Ellipta, opening the door to a new treatment option for patients with Chronic Obstructive Pulmonary Disorder (COPD).
Read More
GSK files triple combo for COPD in Europe
GlaxoSmithKline has filed with the European Medicines Agency its Innoviva-partnered, once-daily, closed triple combination therapy as a treatment for patients with chronic obstructive pulmonary disease (COPD).
Read More
GSK/Innoviva’s triple therapy hits targets in COPD trial
GlaxoSmithKline and Innoviva’s three-drug inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) has come out on top in a trial assessing its effectiveness against the dual therapy Symbicort Turbohaler in patients with chronic obstructive pulmonary disorder (COPD).
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
